speb/financial-data huggingface dataset:
Financial ratios for AUROPHARMA.NS — annual report dated 2023-03-31
Total revenue: 2998432399.5127897
Gross profit: 1549017052.3751523
Operating income: 309086479.90255785
Net income: 234792935.4445798
Capital expenditures: 291438489.64677227
Operating cash flow: 290712545.6760049
Depreciation & amortization: 151593179.0499391
Net tangible assets: 2791465286.2362976
Owner earnings: 94947624.84774661
Return on net tangible assets (%): 3.401354310795083
Capex to operating income (%): 94.29027427490544
Buffett classification: The Gruesome
Shares outstanding: 575377895
Book value: 3270627283.8002443
Debt to equity: 0.19686576530108724
Current ratio: 1.8745504090038263
Quick ratio: 1.1340429345263263
Effective tax rate (%): 26.214354066985646
Interest coverage ratio: 19.67894532764637
COGS to revenue (%): 48.33910370542788
R&D to revenue (%): 0.1604979946890641
SG&A to revenue (%): 9.538764266996193
Free cash flow (dilution-adjusted): -40639464.06820951
Retained earnings: 2924851400.7308164
Inventory turnover: 1.398117545877623
Receivables turnover: 5.511651494051111
Capitalized R&D asset: 10576738.78826653
ROCI (R&D-adjusted, %): 8.918973406628565
FCF margin (%): -1.355357021716179
Rule of 40 score: -1.355357021716179
Financial ratios for AUROPHARMA.NS — annual report dated 2024-03-31
Total revenue: 3442199304.4729586
Gross profit: 1854933445.257225
Operating income: 532621417.4361434
Net income: 380497661.5901187
Capital expenditures: 326184194.74757165
Operating cash flow: 291943878.16284925
Depreciation & amortization: 178907542.87084782
Net tangible assets: 3089841707.6388054
Owner earnings: 233221009.71339494
Return on net tangible assets (%): 7.547992155611678
Capex to operating income (%): 61.24128397196462
Buffett classification: The Good
Shares outstanding: 575377895
Book value: 3579661829.95563
Debt to equity: 0.22269520414863256
Current ratio: 1.98420952969597
Quick ratio: 1.1801989158243251
Effective tax rate (%): 27.648921572880305
Interest coverage ratio: 16.567309485620502
COGS to revenue (%): 46.111968506680135
R&D to revenue (%): 0.2634778519047536
SG&A to revenue (%): 8.717831698862549
Free cash flow (dilution-adjusted): -135145700.92337212
Retained earnings: 3213984890.2746134
Inventory turnover: 1.3495003685680291
Receivables turnover: 5.959321034558644
Capitalized R&D asset: 15132896.962819634
ROCI (R&D-adjusted, %): 13.499548291600473
Rosenberg metric: 63.56804822986121
FCF margin (%): -3.926143984392691
Revenue growth (%): 14.799963642077632
Rule of 40 score: 10.87381965768494
Financial ratios for AUROPHARMA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 3209487577.6397514
Buffett classification: The Gruesome
Shares outstanding: 575377895
Book value: 3689077878.643096
Debt to equity: 0.27285934642622167
Current ratio: 1.828771221247676
Quick ratio: 1.1013348135152135
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for AUROPHARMA.NS — quarterly report dated 2024-12-31
Total revenue: 920054784.9399697
Gross profit: 533598321.4826903
Operating income: 140958153.6309593
Net income: 98590744.84205617
Capital expenditures: 0
Depreciation & amortization: 48785406.224501684
Owner earnings: 147376151.06655785
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 575377895
Effective tax rate (%): 29.527024211359752
Interest coverage ratio: 10.206617150573935
COGS to revenue (%): 42.00363606418223
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for AUROPHARMA.NS — quarterly report dated 2025-03-31
Total revenue: 979789572.1299976
Gross profit: 579055412.6724339
Operating income: 157527472.52747253
Net income: 105619593.17278466
Capital expenditures: 0
Depreciation & amortization: 51955810.147299506
Net tangible assets: 3321790974.9824643
Owner earnings: 157575403.32008415
Return on net tangible assets (%): 4.743688104002871
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 575377895
Book value: 3816568856.6752396
Debt to equity: 0.2530979176296209
Current ratio: 1.850008922283505
Quick ratio: 1.1318863341946854
Effective tax rate (%): 32.37684350867732
Interest coverage ratio: 11.715266910102592
COGS to revenue (%): 40.900022908632735
Retained earnings: 3533043020.808978
Inventory turnover: 0.325111061371129
Receivables turnover: 1.4586185352066594
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.838715218774206
Revenue growth (%): 6.492525028705268
Rule of 40 score: 6.492525028705268
Financial ratios for AUROPHARMA.NS — annual report dated 2025-03-31
Total revenue: 3668240589.1980357
Gross profit: 2145416179.5651157
Operating income: 579380406.8272153
Net income: 407514613.0465279
Capital expenditures: 229719429.50666353
Operating cash flow: 458805237.3158756
Depreciation & amortization: 192824409.63292027
Net tangible assets: 3321790974.9824643
Owner earnings: 370619593.17278457
Return on net tangible assets (%): 11.157221991511404
Capex to operating income (%): 39.64915395821647
Buffett classification: The Good
Shares outstanding: 575377895
Book value: 3816568856.6752396
Debt to equity: 0.2530979176296209
Current ratio: 1.850008922283505
Quick ratio: 1.1318863341946854
Effective tax rate (%): 31.240217200357662
Interest coverage ratio: 10.838990464526288
COGS to revenue (%): 41.513754962453156
R&D to revenue (%): 0.3030773344364371
SG&A to revenue (%): 9.747680948482271
Free cash flow (dilution-adjusted): 164258826.28010285
Retained earnings: 3533043020.808978
Inventory turnover: 1.2354501067934278
Receivables turnover: 5.460931476714823
Capitalized R&D asset: 18782225.643077012
ROCI (R&D-adjusted, %): 14.12187505303512
Rosenberg metric: 32.02876532319847
FCF margin (%): 4.477864040973761
Revenue growth (%): 6.566769228944653
Rule of 40 score: 11.044633269918414
Financial ratios for AUROPHARMA.NS — quarterly report dated 2025-06-30
Total revenue: 911744675.871753
Gross profit: 532711209.9227709
Operating income: 140149777.6737655
Net income: 96507137.8422654
Capital expenditures: 0
Depreciation & amortization: 47472501.75520712
Owner earnings: 143979639.59747252
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 575377895
Effective tax rate (%): 31.703679151474972
Interest coverage ratio: 12.252890025575448
COGS to revenue (%): 41.57232567183066
Capitalized R&D asset: 0
Revenue growth (%): -6.9448479748890914
Rule of 40 score: -6.9448479748890914
Financial ratios for AUROPHARMA.NS — quarterly report dated 2025-12-31
Total revenue: 958506182.4663029
Gross profit: 570714047.0090231
Operating income: 145773643.75626603
Net income: 101402472.98652111
Capital expenditures: 0
Depreciation & amortization: 51768965.133117974
Owner earnings: 153171438.1196391
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 575377895
Effective tax rate (%): 32.02940561216867
Interest coverage ratio: 14.105960978764688
COGS to revenue (%): 40.457969134790936
Capitalized R&D asset: 0
Revenue growth (%): 5.128794039826937
Rule of 40 score: 5.128794039826937
Financial ratios for CAI — annual report dated 2022-12-31
Total revenue: 258485000
Gross profit: 80022000
Operating income: -315756000
Net income: -320827000
Capital expenditures: 42255000
Operating cash flow: -285706000
Depreciation & amortization: 48253000
Net tangible assets: -1721457000
Owner earnings: -314829000
Buffett classification: The Gruesome
Shares outstanding: 282680695
Book value: -1702113000
Debt to equity: -0.1591386705818004
Current ratio: 3.769330781704235
Quick ratio: 3.4263509269133565
Interest coverage ratio: -11.834932533733133
COGS to revenue (%): 69.04191732595702
R&D to revenue (%): 39.177515136274835
SG&A to revenue (%): 113.93697893494787
Free cash flow (dilution-adjusted): -350862000
Retained earnings: -1678650000
Inventory turnover: 3.8006431552943183
Receivables turnover: 6.4256593830014666
Capitalized R&D asset: 101268000
ROCI (R&D-adjusted, %): -36.41094540206282
FCF margin (%): -135.73785712904035
Rule of 40 score: -135.73785712904035
Financial ratios for CAI — annual report dated 2023-12-31
Total revenue: 306128000
Gross profit: 89310000
Operating income: -319551000
Net income: -341415000
Capital expenditures: 22319000
Operating cash flow: -276100000
Depreciation & amortization: 49001000
Net tangible assets: -2164294000
Owner earnings: -314733000
Buffett classification: The Gruesome
Shares outstanding: 282680695
Book value: -2144950000
Debt to equity: -0.10121774400335672
Current ratio: 2.5501061615758163
Quick ratio: 2.035085875254893
Interest coverage ratio: -10.109174311926605
COGS to revenue (%): 70.8259290231537
R&D to revenue (%): 38.18108764961062
SG&A to revenue (%): 95.3777504834579
Free cash flow (dilution-adjusted): -313660000
Retained earnings: -2119175000
Inventory turnover: 4.425037756643128
Receivables turnover: 5.53586864138592
Capitalized R&D asset: 184732560
ROCI (R&D-adjusted, %): -54.803578371077286
Rosenberg metric: 0.0917170280838962
FCF margin (%): -102.46040871792192
Revenue growth (%): 18.431630462115788
Rule of 40 score: -84.02877825580613
Financial ratios for CAI — annual report dated 2024-12-31
Total revenue: 412260000
Gross profit: 178782000
Operating income: -257122000
Net income: -281890000
Capital expenditures: 8444000
Operating cash flow: -245199000
Depreciation & amortization: 48913000
Net tangible assets: -2518182000
Owner earnings: -241421000
Buffett classification: The Gruesome
Shares outstanding: 282680695
Book value: -2498838000
Debt to equity: -0.16978251491293153
Current ratio: 1.3041052332505154
Quick ratio: 1.064888195716436
Interest coverage ratio: -5.139870064967516
COGS to revenue (%): 56.633677776160674
R&D to revenue (%): 27.632076844709648
SG&A to revenue (%): 78.1031387959055
Free cash flow (dilution-adjusted): -272286000
Retained earnings: -2472300000
Inventory turnover: 5.900080865258263
Receivables turnover: 4.671819047187344
Capitalized R&D asset: 225646050
ROCI (R&D-adjusted, %): -62.851978941820676
Rosenberg metric: 0.7654834321500988
FCF margin (%): -66.04715470819386
Revenue growth (%): 34.66915799926828
Rule of 40 score: -31.37799670892558
Financial ratios for CAI — quarterly report dated 2025-03-31
Total revenue: 120915000
Gross profit: 57063000
Operating income: -57951000
Net income: -102581000
Capital expenditures: 2689000
Operating cash flow: -31338000
Depreciation & amortization: 7045000
Net tangible assets: -2619209000
Owner earnings: -98225000
Buffett classification: The Gruesome
Shares outstanding: 282680695
Book value: -2599865000
Debt to equity: -0.16147992299600172
Current ratio: 1.0533914883669426
Quick ratio: 0.8285308266791344
Interest coverage ratio: -4.533797527773431
COGS to revenue (%): 52.807344001984866
R&D to revenue (%): 19.07621056113799
SG&A to revenue (%): 76.04350163337882
Free cash flow (dilution-adjusted): -48718000
Retained earnings: -2583231000
Inventory turnover: 1.7468811556139199
Receivables turnover: 1.5081572579639284
Capitalized R&D asset: 23066000
ROCI (R&D-adjusted, %): -27.991496542730964
FCF margin (%): -40.291113592192865
Rule of 40 score: -40.291113592192865
Financial ratios for HUBC — annual report dated 2021-12-31
Total revenue: 9526774.193548387
Gross profit: 1555806.4516129033
Operating income: -4225806.451612903
Net income: -4203225.806451613
Capital expenditures: 146129.03225806452
Operating cash flow: -1703225.8064516129
Depreciation & amortization: 1663548.387096774
Net tangible assets: 3283225.8064516126
Owner earnings: -2685806.4516129037
Return on net tangible assets (%): -81.8038907447436
Buffett classification: The Gruesome
Shares outstanding: 6086861
Book value: 21218709.677419357
Debt to equity: 0.3521390130438748
Current ratio: 1.3109489435692079
Quick ratio: 1.2625270035302174
Interest coverage ratio: -152.32558139534882
COGS to revenue (%): 83.67250194697456
R&D to revenue (%): 19.62550367385636
SG&A to revenue (%): 34.581654420478785
Free cash flow (dilution-adjusted): -3751612.9032258065
Retained earnings: -5628064.516129032
Inventory turnover: 13.444504896626768
Receivables turnover: 1.0862512873326469
Capitalized R&D asset: 1869677.4193548386
ROCI (R&D-adjusted, %): -10.427910127582702
FCF margin (%): -39.37967697152338
Rule of 40 score: -39.37967697152338
Financial ratios for MSS — annual report dated 2022-04-30
Total revenue: 41984221
Gross profit: 8286624
Operating income: -826590
Net income: -562744
Capital expenditures: 58545
Operating cash flow: 1487476
Depreciation & amortization: 437408
Net tangible assets: -742765
Owner earnings: -183881
Buffett classification: The Gruesome
Shares outstanding: 810539
Book value: -847044
Debt to equity: -24.689600540231677
Current ratio: 1.2008912294862233
Quick ratio: 0.8932579607016877
COGS to revenue (%): 80.26252767676695
SG&A to revenue (%): 21.706283415381222
Free cash flow (dilution-adjusted): 1423689
Retained earnings: -729093
Inventory turnover: 14.522579049190233
Receivables turnover: 8.213221213333503
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -4.454286696577821
FCF margin (%): 3.3910096843287865
Rule of 40 score: 3.3910096843287865
Financial ratios for MSS — annual report dated 2023-04-30
Total revenue: 55399112
Gross profit: 12451160
Operating income: 83647
Net income: 1639301
Capital expenditures: 49388
Operating cash flow: 484191
Depreciation & amortization: 371696
Net tangible assets: -1895230
Owner earnings: 1961609
Return on net tangible assets (%): -103.50242450784337
Capex to operating income (%): 59.04336078998649
Buffett classification: The Good
Shares outstanding: 810539
Book value: 792257
Debt to equity: 34.780467701768494
Current ratio: 0.9896252816159642
Quick ratio: 0.6338260918482188
Effective tax rate (%): 17.030479500067567
COGS to revenue (%): 77.5246216942972
SG&A to revenue (%): 22.324388520884593
Free cash flow (dilution-adjusted): 434803
Retained earnings: 522710
Inventory turnover: 14.416970069681428
Receivables turnover: 46.56162285825709
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.3191249779055731
FCF margin (%): 0.784855540644767
Revenue growth (%): 31.952220811718764
Rule of 40 score: 32.73707635236353
Financial ratios for NATCAPSUQ.NS — annual report dated 2022-03-31
Total revenue: 17127258.34102598
Gross profit: 9018066.728207834
Operating income: 3028933.1399182384
Net income: 1834880.6540946856
Capital expenditures: 5842212.844520639
Operating cash flow: -68811.81590399578
Depreciation & amortization: 664697.3493340367
Net tangible assets: 10712923.644995384
Owner earnings: -3342634.8410919164
Return on net tangible assets (%): -31.201891769792006
Capex to operating income (%): 192.88021803869663
Buffett classification: The Gruesome
Shares outstanding: 10411154
Book value: 10943135.962020308
Debt to equity: 0.636038263812065
Current ratio: 1.6883577555396712
Quick ratio: 1.5860949785561116
Effective tax rate (%): 28.2289221881206
Interest coverage ratio: 11.715582759500128
COGS to revenue (%): 47.34669992916321
R&D to revenue (%): 1.633635159690782
SG&A to revenue (%): 7.8217684560657865
Free cash flow (dilution-adjusted): -6145602.004483714
Retained earnings: 7356507.978372676
Inventory turnover: 13.431773006268976
Receivables turnover: 4.937762806718727
Capitalized R&D asset: 279796.91415007255
ROCI (R&D-adjusted, %): 20.04642418661756
FCF margin (%): -35.881995133819956
Rule of 40 score: -35.881995133819956
Financial ratios for NATCAPSUQ.NS — annual report dated 2023-03-31
Total revenue: 20063288.672350794
Gross profit: 10086138.855054813
Operating income: 3317308.160779537
Net income: 2246796.58952497
Capital expenditures: 12871181.485992692
Operating cash flow: 2097040.1948842877
Depreciation & amortization: 877965.8952496955
Net tangible assets: 14874056.029232644
Owner earnings: -9746419.001218027
Return on net tangible assets (%): -65.52630285957613
Capex to operating income (%): 388.0007784072759
Buffett classification: The Gruesome
Shares outstanding: 10411154
Book value: 18056784.409257002
Debt to equity: 0.6529293836874066
Current ratio: 1.5163350363000807
Quick ratio: 1.3841489647754772
Effective tax rate (%): 26.193648545375247
Interest coverage ratio: 7.996916933376398
COGS to revenue (%): 49.72838690720473
R&D to revenue (%): 1.4501613651320184
SG&A to revenue (%): 7.88382196168519
Free cash flow (dilution-adjusted): -10800767.356881851
Retained earnings: 8947454.323995128
Inventory turnover: 9.256893590091313
Receivables turnover: 3.1598275825687283
Capitalized R&D asset: 478413.9933818885
ROCI (R&D-adjusted, %): 12.430667252689362
Rosenberg metric: 3.817312031804985
FCF margin (%): -53.833484296950694
Revenue growth (%): 17.14244202349632
Rule of 40 score: -36.69104227345437
Financial ratios for NATCAPSUQ.NS — annual report dated 2024-03-31
Total revenue: 18142427.149538312
Gross profit: 8266458.808010553
Operating income: 1237774.3134668425
Net income: 665967.1423432066
Capital expenditures: 8563280.96894112
Operating cash flow: -1001774.7931406643
Depreciation & amortization: 1039429.1881520565
Net tangible assets: 24382407.96258544
Owner earnings: -6857884.638445858
Return on net tangible assets (%): -28.126363273755455
Capex to operating income (%): 691.8289445639327
Buffett classification: The Gruesome
Shares outstanding: 10411154
Book value: 27437846.264540114
Debt to equity: 0.47642482087304344
Current ratio: 1.6181570249662687
Quick ratio: 1.3692827035111756
Effective tax rate (%): 31.02870130031421
Interest coverage ratio: 2.0123213693876356
COGS to revenue (%): 54.4357613241351
R&D to revenue (%): 1.3745813495565131
SG&A to revenue (%): 7.13399524224055
Free cash flow (dilution-adjusted): -9604676.819762561
Retained earnings: 9365415.517448135
Inventory turnover: 4.326381483213121
Receivables turnover: 2.7775121857186127
Capitalized R&D asset: 536651.9424278527
ROCI (R&D-adjusted, %): 3.323900453076315
Rosenberg metric: -6.25426934576689
FCF margin (%): -52.94041828359764
Revenue growth (%): -9.574011290878847
Rule of 40 score: -62.51442957447648
Financial ratios for NATCAPSUQ.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 27867367.4151935
Buffett classification: The Gruesome
Shares outstanding: 10411154
Book value: 30856999.522216912
Debt to equity: 0.3860409050580874
Current ratio: 1.702614003853438
Quick ratio: 1.4238756704717368
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for NATCAPSUQ.NS — quarterly report dated 2024-12-31
Total revenue: 5108660.683063294
Gross profit: 2510956.9879939384
Operating income: 225329.29245832845
Net income: 12320.783308077864
Capital expenditures: 0
Depreciation & amortization: 271943.11691339314
Owner earnings: 284263.900221471
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 10411154
Effective tax rate (%): 78.96833300139414
Interest coverage ratio: 1.2545265753780257
COGS to revenue (%): 50.849016136098136
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for NEPHROPLUS.NS — annual report dated 2023-03-31
Total revenue: 50490255.78562729
Gross profit: 23521315.468940318
Operating income: 443848.96467722295
Net income: -1435931.790499391
Capital expenditures: 8717295.980511572
Operating cash flow: 1372594.3970767357
Depreciation & amortization: 5709987.819732035
Net tangible assets: 44670889.159561515
Owner earnings: -4443239.951278929
Return on net tangible assets (%): -9.946611842464035
Capex to operating income (%): 1964.0230515916573
Buffett classification: The Gruesome
Shares outstanding: 100559014
Book value: 47336297.19853838
Debt to equity: 0.549948408644704
Current ratio: 1.8569923201594385
Quick ratio: 1.7065396047258796
Interest coverage ratio: 0.24982860276977925
COGS to revenue (%): 53.414148724443635
SG&A to revenue (%): 3.6844581147096074
Free cash flow (dilution-adjusted): -7863093.788063338
Retained earnings: -16414738.124238735
Inventory turnover: 8.428114651136234
Receivables turnover: 2.615217185577742
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0.7412274189053673
FCF margin (%): -15.57348772691635
Rule of 40 score: -15.57348772691635
Financial ratios for NEPHROPLUS.NS — annual report dated 2024-03-31
Total revenue: 64702122.55666147
Gross profit: 30662309.62945197
Operating income: 6412399.56829356
Net income: 4213095.0953351725
Capital expenditures: 9275572.610624775
Operating cash flow: 8667705.959947236
Depreciation & amortization: 6581724.427389375
Net tangible assets: 43393092.69696606
Owner earnings: 1519246.9120997712
Return on net tangible assets (%): 3.501126141686585
Capex to operating income (%): 144.65057131636527
Buffett classification: The Gruesome
Shares outstanding: 100559014
Book value: 49611344.2858856
Debt to equity: 0.6474188378787988
Current ratio: 1.6078240616691055
Quick ratio: 1.501003771873776
Effective tax rate (%): -5.946744669943609
Interest coverage ratio: 2.8143684210526314
COGS to revenue (%): 52.61004057077088
SG&A to revenue (%): 2.692423885786515
Free cash flow (dilution-adjusted): -1149418.3954910662
Retained earnings: -11622017.028420674
Inventory turnover: 10.954270057500096
Receivables turnover: 2.662253844977229
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.49058626418095
FCF margin (%): -1.7764771078174262
Revenue growth (%): 28.14774167787
Rule of 40 score: 26.37126457005257
Financial ratios for NEPHROPLUS.NS — quarterly report dated 2024-12-31
Total revenue: 22993006.177876208
Gross profit: 12805455.181256555
Operating income: 3021564.2848816877
Net income: 2343979.484788437
Capital expenditures: 0
Depreciation & amortization: 2118195.593892062
Owner earnings: 4462175.0786804985
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 100559014
Effective tax rate (%): 23.9303953092491
Interest coverage ratio: 5.3414382855965385
COGS to revenue (%): 44.307172875994254
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for NEPHROPLUS.NS — annual report dated 2025-03-31
Total revenue: 87484685.52723871
Gross profit: 46306406.35959785
Operating income: 11571662.380173018
Net income: 7843815.758709375
Capital expenditures: 11664133.738601822
Operating cash flow: 15822656.067336917
Depreciation & amortization: 8471942.950666355
Net tangible assets: 59838438.15758709
Owner earnings: 4651624.970773907
Return on net tangible assets (%): 7.773640345564592
Capex to operating income (%): 100.79911904954335
Buffett classification: The Gruesome
Shares outstanding: 100559014
Book value: 68285363.57259762
Debt to equity: 0.44131358144742533
Current ratio: 1.9209813487380896
Quick ratio: 1.8272037196850948
Effective tax rate (%): 23.263606939853837
Interest coverage ratio: 5.246409074044628
COGS to revenue (%): 47.06912863602835
SG&A to revenue (%): 3.0142554760912095
Free cash flow (dilution-adjusted): 3293196.165536591
Retained earnings: -3578442.8337619826
Inventory turnover: 13.230627652781429
Receivables turnover: 2.808919851210696
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 13.891223958516067
FCF margin (%): 3.7643116000128285
Revenue growth (%): 35.21146149514014
Rule of 40 score: 38.975773095152974
Financial ratios for NEPHROPLUS.NS — quarterly report dated 2025-03-31
Total revenue: 25624620.06079027
Gross profit: 14413023.1470657
Operating income: 3732172.083235913
Net income: 2907177.928454524
Capital expenditures: 0
Depreciation & amortization: 2265022.211830722
Net tangible assets: 59838438.15758709
Owner earnings: 5172200.140285246
Return on net tangible assets (%): 8.643608188208448
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 100559014
Book value: 68285363.57259762
Debt to equity: 0.44131358144742533
Current ratio: 1.9209813487380896
Quick ratio: 1.8272037196850948
Effective tax rate (%): 16.89335962303245
Interest coverage ratio: 5.219914977109222
COGS to revenue (%): 43.753222046324474
Retained earnings: -3578442.8337619826
Inventory turnover: 3.602298764226421
Receivables turnover: 0.8227440441112992
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.480293025899392
Revenue growth (%): 11.445279762705377
Rule of 40 score: 11.445279762705377
Financial ratios for NEPHROPLUS.NS — quarterly report dated 2025-09-30
Capital expenditures: 0
Net tangible assets: 69409131.90529875
Buffett classification: The Gruesome
Shares outstanding: 100559014
Book value: 80834272.82976326
Debt to equity: 0.3646764295676429
Current ratio: 1.7739870384489707
Quick ratio: 1.6813037795447117
Retained earnings: -1728297.6324689966
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RGG.L — annual report dated 2023-12-31
Total revenue: 938010.1265822784
Gross profit: 763970.8860759493
Operating income: -1031650.6329113924
Net income: -1556122.7848101265
Capital expenditures: 147146.83544303797
Operating cash flow: -89968.35443037974
Depreciation & amortization: 168108.86075949366
Net tangible assets: -2394462.0253164554
Owner earnings: -1535160.759493671
Buffett classification: The Gruesome
Shares outstanding: 148792459
Book value: -2049207.594936709
Debt to equity: -0.5579513909050364
Current ratio: 0.05503466071526682
Quick ratio: 0.05503466071526682
Interest coverage ratio: -14.58620134228188
COGS to revenue (%): 18.55408972400503
SG&A to revenue (%): 92.92159000739514
Free cash flow (dilution-adjusted): -237115.18987341772
Retained earnings: -7527429.113924051
Capitalized R&D asset: 0
FCF margin (%): -25.278531985296105
Rule of 40 score: -25.278531985296105
Financial ratios for RGG.L — annual report dated 2024-12-31
Total revenue: 1592180
Gross profit: 1262226.25
Operating income: -1037157.5
Net income: -866702.5
Capital expenditures: 243005
Operating cash flow: 287473.75
Depreciation & amortization: 192088.75
Net tangible assets: -2262586.25
Owner earnings: -917618.75
Buffett classification: The Gruesome
Shares outstanding: 148792459
Book value: -1863422.5
Debt to equity: -0.18975701967750203
Current ratio: 0.14286941495600688
Quick ratio: 0.14286941495600688
Interest coverage ratio: -22.602794954915687
COGS to revenue (%): 20.72339496790564
SG&A to revenue (%): 67.12698941074503
Free cash flow (dilution-adjusted): 44468.75
Retained earnings: -8300233.75
Capitalized R&D asset: 0
FCF margin (%): 2.792947405444108
Revenue growth (%): 69.74017176139094
Rule of 40 score: 72.53311916683505
Financial ratios for RGG.L — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: -2262586.25
Buffett classification: The Gruesome
Shares outstanding: 148792459
Book value: -1863422.5
Debt to equity: -0.18975701967750203
Current ratio: 0.14286941495600688
Quick ratio: 0.14286941495600688
Retained earnings: -8300233.75
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for RGG.L — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: -1247257.5342465753
Buffett classification: The Gruesome
Shares outstanding: 148792459
Book value: -842549.3150684931
Debt to equity: -1.065564228588709
Current ratio: 0.7527136407341605
Quick ratio: 0.7527136407341605
Retained earnings: -9906524.657534247
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SNTIA.OL — annual report dated 2022-12-31
Total revenue: 1052530364.3724695
Gross profit: 179959514.17004046
Operating income: 27631578.94736842
Net income: 19635627.53036437
Capital expenditures: 1720647.773279352
Operating cash flow: 103238866.39676112
Depreciation & amortization: 13056680.161943318
Net tangible assets: -43319838.05668016
Owner earnings: 30971659.919028334
Return on net tangible assets (%): -71.49532710280373
Capex to operating income (%): 6.227106227106226
Buffett classification: The Great
Shares outstanding: 100450082
Book value: 80364372.46963567
Debt to equity: 0.24937027707808548
Current ratio: 1.0826326471440997
Quick ratio: 1.0826326471440997
Effective tax rate (%): 25.482625482625483
Interest coverage ratio: 10.111111111111112
COGS to revenue (%): 82.90220213482066
SG&A to revenue (%): 0.019232618521011637
Free cash flow (dilution-adjusted): 101518218.62348178
Retained earnings: 51315789.47368421
Receivables turnover: 9.121929824561404
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 15.7621247113164
FCF margin (%): 9.645158188287336
Rule of 40 score: 9.645158188287336
Financial ratios for SNTIA.OL — annual report dated 2023-12-31
Total revenue: 1166895874.2632613
Gross profit: 229076620.82514736
Operating income: 62278978.38899804
Net income: 50491159.135559924
Capital expenditures: 1866404.7151277014
Operating cash flow: 202652259.3320236
Depreciation & amortization: 12573673.870333988
Net tangible assets: 53045186.64047151
Owner earnings: 61198428.29076622
Return on net tangible assets (%): 115.3703703703704
Capex to operating income (%): 2.9968454258675075
Buffett classification: The Great
Shares outstanding: 100450082
Book value: 174557956.77799606
Debt to equity: 0.10073157006190209
Current ratio: 1.2131837307152875
Quick ratio: 1.2131837307152875
Effective tax rate (%): 23.660714285714285
Interest coverage ratio: 70.44444444444446
COGS to revenue (%): 80.3687179055476
SG&A to revenue (%): 0.016836434043269635
Free cash flow (dilution-adjusted): 200687622.7897839
Retained earnings: 145677799.60707268
Receivables turnover: 18.388544891640866
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 27.505422993492413
FCF margin (%): 17.19841737519993
Revenue growth (%): 10.865768225031472
Rule of 40 score: 28.064185600231404
Financial ratios for SNTIA.OL — annual report dated 2024-12-31
Total revenue: 929479258.6054722
Gross profit: 203618711.3857017
Operating income: 49955869.3733451
Net income: 42718446.60194175
Capital expenditures: 1765225.06619594
Operating cash flow: 81112091.79170345
Depreciation & amortization: 8473080.317740511
Net tangible assets: 42718446.60194175
Owner earnings: 49426301.85348632
Return on net tangible assets (%): 115.70247933884296
Capex to operating income (%): 3.53356890459364
Buffett classification: The Great
Shares outstanding: 100450082
Book value: 159046778.46425414
Debt to equity: 0.12430632630410658
Current ratio: 1.209202175883953
Quick ratio: 1.209202175883953
Effective tax rate (%): 24.375
Interest coverage ratio: 40.42857142857143
COGS to revenue (%): 78.09324850441554
SG&A to revenue (%): 0.04747887190200361
Free cash flow (dilution-adjusted): 79346866.7255075
Retained earnings: 70609002.6478376
Receivables turnover: 21.848547717842322
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 24.003392705682785
FCF margin (%): 8.53670116798025
Revenue growth (%): -20.345998378620198
Rule of 40 score: -11.809297210639949
Financial ratios for SNTIA.OL — quarterly report dated 2025-03-31
Total revenue: 270610687.02290076
Gross profit: 58301526.71755725
Operating income: 9828244.27480916
Net income: 8492366.41221374
Capital expenditures: 477099.23664122133
Operating cash flow: -24809160.30534351
Depreciation & amortization: 2385496.183206107
Net tangible assets: -17557251.908396944
Owner earnings: 10400763.358778628
Return on net tangible assets (%): -59.23913043478263
Capex to operating income (%): 4.854368932038835
Buffett classification: The Great
Shares outstanding: 100450082
Book value: 106583969.46564889
Debt to equity: 0.20948970456580118
Current ratio: 1.0596026490066224
Quick ratio: 1.0596026490066224
Effective tax rate (%): 21.92982456140351
Interest coverage ratio: 4.681818181818182
COGS to revenue (%): 78.45557122708038
Free cash flow (dilution-adjusted): -25286259.541984733
Retained earnings: 12786259.541984733
Receivables turnover: 3.5229813664596277
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.083874778499703
FCF margin (%): -9.344146685472497
Rule of 40 score: -9.344146685472497
Financial ratios for SUPX — annual report dated 2021-06-30
Total revenue: 4700749.253731343
Gross profit: 885077.6119402985
Operating income: 277046.2686567164
Net income: 317258.20895522385
Capital expenditures: 0
Operating cash flow: 453475.37313432834
Depreciation & amortization: 91382.0895522388
Net tangible assets: 1112824.6268656715
Owner earnings: 408640.29850746266
Return on net tangible assets (%): 36.72099705938566
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 43244701
Book value: 1112824.6268656717
Debt to equity: 0.3718089975422231
Current ratio: 2.1727246502688935
Quick ratio: 2.1727246502688935
Effective tax rate (%): 6.546612824159665
Interest coverage ratio: 33.92816669713032
COGS to revenue (%): 81.17156299630864
SG&A to revenue (%): 14.485655192471697
Free cash flow (dilution-adjusted): 453475.37313432834
Retained earnings: 104997.01492537312
Receivables turnover: 2.8573183410780416
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 19.347028284531735
FCF margin (%): 9.64687433124348
Rule of 40 score: 9.64687433124348
Financial ratios for SUPX — annual report dated 2022-06-30
Total revenue: 6921273.381294965
Gross profit: 1041700.0000000001
Operating income: -161465.4676258993
Net income: -47417.9856115108
Capital expenditures: 8176.258992805756
Operating cash flow: -164806.4748201439
Depreciation & amortization: 78566.90647482015
Net tangible assets: 866272.6618705037
Owner earnings: 22972.661870503594
Buffett classification: The Gruesome
Shares outstanding: 43244701
Book value: 866272.6618705038
Debt to equity: 0.5212167568155638
Current ratio: 1.4366496919186034
Quick ratio: 1.4366496919186034
Interest coverage ratio: -14.304461440407904
COGS to revenue (%): 84.94930134077295
SG&A to revenue (%): 17.383585380076234
Free cash flow (dilution-adjusted): -172982.73381294965
Retained earnings: -95616.54676258993
Receivables turnover: 9.165895741731415
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -14.041063967022701
FCF margin (%): -2.499290582574629
Revenue growth (%): 47.23766377883318
Rule of 40 score: 44.73837319625855
Financial ratios for SUPX — annual report dated 2023-06-30
Total revenue: 4515243.382352941
Gross profit: 939931.6176470588
Operating income: -56710.294117647056
Net income: 28439.70588235294
Capital expenditures: 10750
Operating cash flow: 33137.5
Depreciation & amortization: 70619.11764705883
Net tangible assets: 803431.6176470588
Owner earnings: 88308.82352941176
Return on net tangible assets (%): 10.991454853125425
Buffett classification: The Gruesome
Shares outstanding: 43244701
Book value: 803431.6176470588
Debt to equity: 0.36253680215472783
Current ratio: 1.2691686309823345
Quick ratio: 1.2691686309823345
Effective tax rate (%): 59.132740931711794
Interest coverage ratio: -6.478998655913979
COGS to revenue (%): 79.18314611078063
SG&A to revenue (%): 22.422363070455294
Free cash flow (dilution-adjusted): 22387.5
Retained earnings: -181830.88235294117
Receivables turnover: 7.244187349662667
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -5.79898224951729
FCF margin (%): 0.4958204487381063
Revenue growth (%): -34.76282276964268
Rule of 40 score: -34.267002320904574
Financial ratios for TTST.L — annual report dated 2022-03-31
Capital expenditures: 1312504285.902677
Operating cash flow: 5852695503.099037
Depreciation & amortization: 1201222471.3174205
Buffett classification: The Gruesome
Shares outstanding: 1247184761
Free cash flow (dilution-adjusted): 4465091652.380324
Retained earnings: 7338492680.996967
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TTST.L — annual report dated 2023-03-31
Total revenue: 29431942752.740562
Gross profit: 11643863580.998783
Operating income: 2595267965.89525
Net income: 1067040194.8842875
Capital expenditures: 1682678440.9257004
Operating cash flow: 2641057247.25944
Depreciation & amortization: 1137808769.7929356
Net tangible assets: 11638000000
Owner earnings: 522170523.7515228
Return on net tangible assets (%): 4.486771986179092
Capex to operating income (%): 64.83640468105777
Buffett classification: The Good
Shares outstanding: 1247184761
Book value: 12810622411.693054
Debt to equity: 0.8071583598454429
Current ratio: 0.8907490025451429
Quick ratio: 0.3314678751135849
Effective tax rate (%): 55.715399734139396
Interest coverage ratio: 3.3827853366567706
COGS to revenue (%): 60.43800547310265
SG&A to revenue (%): 5.522528180270965
Free cash flow (dilution-adjusted): 918464068.2095007
Retained earnings: 5866786845.310597
Inventory turnover: 2.6838049130640207
Receivables turnover: 29.263561432149242
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.171566463641335
FCF margin (%): 3.1206369077487337
Rule of 40 score: 3.1206369077487337
Financial ratios for TTST.L — annual report dated 2024-03-31
Total revenue: 27257009233.72107
Gross profit: 10998796018.70728
Operating income: 1484795539.0334573
Net income: -532130950.95335174
Capital expenditures: 2126298117.2802494
Operating cash flow: 2434424991.006116
Depreciation & amortization: 1185796858.1364672
Net tangible assets: 10175253627.533278
Owner earnings: -1472632210.0971339
Return on net tangible assets (%): -14.472683079980728
Capex to operating income (%): 143.20477543085727
Buffett classification: The Gruesome
Shares outstanding: 1247184761
Book value: 11084391413.838593
Debt to equity: 0.9421133680555177
Current ratio: 0.7169284053775334
Quick ratio: 0.21737788135135055
Interest coverage ratio: 1.6492300438091154
COGS to revenue (%): 59.64782517261617
SG&A to revenue (%): 5.571531772198567
Free cash flow (dilution-adjusted): 251117640.00479674
Retained earnings: 4175048566.9744573
Inventory turnover: 2.758016832016105
Receivables turnover: 36.288833932303355
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.074453539657919
FCF margin (%): 0.9212956485854141
Revenue growth (%): -7.389704231525708
Rule of 40 score: -6.4684085829402935
Financial ratios for TTST.L — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 8518647873.865265
Buffett classification: The Gruesome
Shares outstanding: 1247184761
Book value: 10810922121.356903
Debt to equity: 1.098141798874455
Current ratio: 0.8050681001900227
Quick ratio: 0.24853002081201664
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for TTST.L — annual report dated 2025-03-31
Total revenue: 25349584989.478603
Gross profit: 10958788870.703764
Operating income: 1739200374.093991
Net income: 399872574.23427635
Capital expenditures: 1684191021.744213
Operating cash flow: 2704884264.6714983
Depreciation & amortization: 1218890577.5075986
Net tangible assets: 9781588730.418516
Owner earnings: -65427870.00233817
Return on net tangible assets (%): -0.6688879670321077
Capex to operating income (%): 96.83708943666515
Buffett classification: The Gruesome
Shares outstanding: 1247184761
Book value: 10679539396.773438
Debt to equity: 1.0377467439961872
Current ratio: 0.7943862467761816
Quick ratio: 0.2764620257310767
Effective tax rate (%): 62.274705302708824
Interest coverage ratio: 2.0265932883346163
COGS to revenue (%): 56.769355887868656
SG&A to revenue (%): 6.607280425437424
Free cash flow (dilution-adjusted): 872931961.6553658
Retained earnings: 3939505494.505494
Inventory turnover: 2.7606870518327677
Receivables turnover: 41.22393090573111
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.696339661349301
FCF margin (%): 3.443574961947811
Revenue growth (%): -6.997921994621083
Rule of 40 score: -3.554347032673272
Financial ratios for TTST.L — quarterly report dated 2025-03-31
Total revenue: 6512390694.41197
Gross profit: 339559270.5167173
Operating income: 399780219.78021973
Net income: 152070376.43207854
Capital expenditures: 0
Depreciation & amortization: 318567921.44026184
Net tangible assets: 9781588730.418516
Owner earnings: 470638297.8723404
Return on net tangible assets (%): 4.811470926075253
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1247184761
Book value: 10679539396.773438
Debt to equity: 1.0377467439961872
Current ratio: 0.7943862467761816
Quick ratio: 0.2764620257310767
Effective tax rate (%): 45.406852783801355
Interest coverage ratio: 1.9117931516422082
COGS to revenue (%): 94.78595056024388
Retained earnings: 3939505494.505494
Inventory turnover: 1.184177417596884
Receivables turnover: 10.590561704619338
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 1.7691143626393704
Rule of 40 score: 0
Financial ratios for TTST.L — quarterly report dated 2025-06-30
Total revenue: 6171784460.566347
Gross profit: 3763797098.057571
Operating income: 548003744.4418442
Net income: 243117247.83524457
Capital expenditures: 0
Depreciation & amortization: 321120992.2770887
Owner earnings: 564238240.1123333
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1247184761
Effective tax rate (%): 34.55143002464885
Interest coverage ratio: 2.5281603083517328
COGS to revenue (%): 39.01606379636611
Capitalized R&D asset: 0
Revenue growth (%): -5.2301259219273195
Rule of 40 score: -5.2301259219273195
Financial ratios for TTST.L — quarterly report dated 2025-09-30
Total revenue: 6563251409.244645
Gross profit: 3809465614.430665
Operating income: 676836527.621195
Net income: 358860202.9312289
Capital expenditures: 0
Depreciation & amortization: 326155580.6087937
Net tangible assets: 8560659526.493799
Owner earnings: 685015783.5400226
Return on net tangible assets (%): 8.001904309124946
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1247184761
Book value: 10815322435.174744
Debt to equity: 0.9969897399103179
Current ratio: 0.7422409548970078
Quick ratio: 0.23433114461547444
Effective tax rate (%): 24.61545019858045
Interest coverage ratio: 3.382352278361202
COGS to revenue (%): 41.95764603707157
Inventory turnover: 0.5357845480207338
Receivables turnover: 10.08286454580724
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 3.0660570921715427
Revenue growth (%): 6.342848671717475
Rule of 40 score: 6.342848671717475
Financial ratios for TTST.L — quarterly report dated 2025-12-31
Total revenue: 6310131447.031302
Gross profit: 3810214993.873232
Operating income: 573787456.8341317
Net income: 304151721.06494373
Capital expenditures: 0
Depreciation & amortization: 339624596.19026405
Owner earnings: 643776317.2552078
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 1247184761
Effective tax rate (%): 29.42537292214321
Interest coverage ratio: 2.947930795689325
COGS to revenue (%): 39.61750201470358
Capitalized R&D asset: 0
Revenue growth (%): -3.8566245056042106
Rule of 40 score: -3.8566245056042106
Financial ratios for UCAR — annual report dated 2022-12-31
Total revenue: 1120114.9425287356
Gross profit: 382040.2298850575
Operating income: -8081752.873563219
Net income: -6597844.827586207
Capital expenditures: 1116235.632183908
Operating cash flow: -1852298.8505747127
Depreciation & amortization: 1106896.551724138
Net tangible assets: 23800431.03448276
Owner earnings: -6607183.908045977
Return on net tangible assets (%): -27.760774157717126
Buffett classification: The Gruesome
Shares outstanding: 23144871
Book value: 29456178.16091954
Debt to equity: 0.17603102212033267
Current ratio: 0.9131360946745563
Quick ratio: 0.820879120879121
Interest coverage ratio: -73.62434554973822
COGS to revenue (%): 65.89276552077989
R&D to revenue (%): 119.95895330938944
SG&A to revenue (%): 509.9409953822473
Free cash flow (dilution-adjusted): -2972988.5057471264
Retained earnings: -22103160.91954023
Inventory turnover: 0.941359721458677
Receivables turnover: 0.2387090847852047
Capitalized R&D asset: 1343678.1609195403
ROCI (R&D-adjusted, %): -21.552699923007093
FCF margin (%): -265.4181631605952
Rule of 40 score: -265.4181631605952
Financial ratios for UCFI — annual report dated 2023-12-31
Total revenue: 0
Gross profit: 0
Operating income: 0
Net income: 0
Capital expenditures: 0
Operating cash flow: 1.9690576652601968
Net tangible assets: 0.14064697609001406
Owner earnings: 0
Return on net tangible assets (%): 0
Buffett classification: The Gruesome
Shares outstanding: 52234983
Book value: 0.1406469760900142
Debt to equity: 0
Current ratio: 1.0714285714285714
Quick ratio: 1.0714285714285714
Free cash flow (dilution-adjusted): 1.9690576652601968
Retained earnings: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 0
Rule of 40 score: 0
Financial ratios for 248A.T — annual report dated 2022-12-31
Total revenue: 4246953.054468853
Gross profit: 2595711.7062894977
Operating income: 783019.8615708698
Net income: 567679.8074029492
Capital expenditures: 1128.4983448690944
Operating cash flow: 1294590.7312669277
Depreciation & amortization: 617845.32049353
Net tangible assets: 1315445.3806801084
Owner earnings: 1184396.6295516102
Return on net tangible assets (%): 90.03768966365264
Capex to operating income (%): 0.14412129247975095
Buffett classification: The Great
Shares outstanding: 2621000
Book value: 2311480.589828468
Debt to equity: 0
Current ratio: 1.5019128522585212
Quick ratio: 1.5019128522585212
Effective tax rate (%): 28.01003663562815
COGS to revenue (%): 38.88043507143427
Free cash flow (dilution-adjusted): 537368.3418597654
Retained earnings: 942416.4911224798
Receivables turnover: 8.37619075882126
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 33.647787559121824
FCF margin (%): 12.653032302636824
Rule of 40 score: 12.653032302636824
Financial ratios for 248A.T — annual report dated 2023-12-31
Total revenue: 5407600.933323906
Gross profit: 3356833.7693558647
Operating income: 1116156.4024605812
Net income: 775677.0133635013
Capital expenditures: 0
Operating cash flow: 2148610.6200947464
Depreciation & amortization: 711800.8909000919
Net tangible assets: 1843533.9036979424
Owner earnings: 1487477.9042635933
Return on net tangible assets (%): 80.68622449958002
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 2621000
Book value: 2948073.2517853356
Debt to equity: 0
Current ratio: 1.6002504384088663
Quick ratio: 1.6002504384088663
Effective tax rate (%): 28.545095714816092
COGS to revenue (%): 37.923658173345345
Free cash flow (dilution-adjusted): 1265841.7591741497
Retained earnings: 1661387.2587145583
Receivables turnover: 16.808725274725276
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 37.67269256010977
FCF margin (%): 23.40856462564576
Revenue growth (%): 27.328954758135637
Rule of 40 score: 50.7375193837814
Financial ratios for 277A.T — annual report dated 2024-05-31
Total revenue: 26602892.640968464
Gross profit: 16868110.86333227
Operating income: 2355074.864606563
Net income: 1659808.8563236701
Capital expenditures: 123440.58617394076
Operating cash flow: -464880.5352022938
Depreciation & amortization: 319241.79675055755
Net tangible assets: 8555323.351385793
Owner earnings: 1855610.066900287
Return on net tangible assets (%): 21.689537504151904
Capex to operating income (%): 5.241471854210573
Buffett classification: The Great
Shares outstanding: 28432500
Book value: 9888480.407773176
Debt to equity: 0
Current ratio: 2.175117113315045
Quick ratio: 2.163953365688964
Effective tax rate (%): 33.742061342265835
COGS to revenue (%): 36.59294464333786
Free cash flow (dilution-adjusted): -1049550.8123606245
Retained earnings: 5969225.8681108635
Inventory turnover: 144.39788299782631
Receivables turnover: 18.301747188105445
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 22.458543663128836
FCF margin (%): -3.9452507158725885
Rule of 40 score: -3.9452507158725885
Financial ratios for 5622.T — annual report dated 2022-03-31
Total revenue: 3490640.878544501
Gross profit: 2357679.0690050814
Operating income: 458982.1340763809
Net income: 516136.6989018194
Capital expenditures: 0
Operating cash flow: 633666.6120308146
Depreciation & amortization: 71365.34994263235
Net tangible assets: 693033.9288641206
Owner earnings: 587502.0488444518
Return on net tangible assets (%): 84.77248001513648
Capex to operating income (%): 0
Buffett classification: The Great
Shares outstanding: 650000
Book value: 896180.9539419767
Debt to equity: 0.17351305874606776
Current ratio: 1.5868962479270317
Quick ratio: 1.5868962479270317
Effective tax rate (%): 5.790575916230367
Interest coverage ratio: 238.3191489361702
COGS to revenue (%): 32.457128904415775
Free cash flow (dilution-adjusted): 602786.4284543517
Retained earnings: -62678.24946730045
Receivables turnover: 4.704255530643576
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 21.928948718249913
FCF margin (%): 17.26864634398302
Rule of 40 score: 17.26864634398302